Tresiba FlexTouch

Tresiba FlexTouch

insulin degludec

Manufacturer:

Novo Nordisk

Distributor:

Novo Nordisk
Concise Prescribing Info
Contents
Insulin degludec
Indications/Uses
Treatment of DM in adults, adolescents & childn from ≥1 yr.
Dosage/Direction for Use
Once-daily SC administration at any time of the day, preferably at the same time every day. Type 2 DM Daily starting dose of 10 u followed by individual dosage adjustments. Type 1 DM Once daily w/ meal-time insulin & requiring individual dosage adjustments.
Special Precautions
For SC use only. Inadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycemia & diabetic ketoacidosis. Concomitant illness, especially infections, usually increases the patient's insulin requirement. Omission of meal or unplanned strenuous physical exercise may lead to hypoglycemia. Intensified insulin therapy may change the usual warning symptoms of hypoglycemia. Shifting from other types of insulin should be done under strict medical supervision. Concomitant diseases in the kidney, liver or those affecting the adrenal, pituitary or thyroid gland may require changes in the insulin dose. Cases of cardiac failure have been reported when thiazolidinediones were used in combination w/ insulin, especially in patients w/ risk factors for development of cardiac failure. Abrupt improvement in glycemic control may be associated w/ temporary worsening of diabetic retinopathy. In elderly patients & patients w/ renal or hepatic impairment, glucose monitoring should be intensified & the dosage should be adjusted on an individual basis. Insulin administration may cause insulin antibodies to form which may necessitate dose adjustment. May impair ability to drive or operate machinery (as a result of hypoglycemia). Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
Hypoglycemia, inj site reactions. Lipodystrophy, peripheral edema, urticaria.
Drug Interactions
Insulin requirement may be reduced by oral antidiabetics, GLP-1 receptor agonists, MAOIs, β-blockers, ACE inhibitors, salicylates, anabolic steroids & sulphonamides. Insulin requirement may be increased by OCs, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone & danazol. Symptoms of hypoglycemia may be masked by β-blockers. Insulin requirement may be increased or decreased by octreotide/lanreotide. Hypoglycemic effect may be intensified or reduced by alcohol.
ATC Classification
A10AE06 - insulin degludec ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.
Presentation/Packing
Form
Tresiba FlexTouch soln for inj 100 units/mL
Packing/Price
3 mL x 5 × 1's (P6,950/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in